Abstracts Archive - Page 2127 of 2607 - ACR Meeting Abstracts

Abstract Number: 1599 • 2014 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes
Megan E. B. Clowse, Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: While it has long been reported that rheumatoid arthritis (RA) improves with pregnancy, there is very limited information about ankylosing spondylitis (AS) or…
Abstract Number: 1597 • 2014 ACR/ARHP Annual Meeting
Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Frank Zhang¹, Thomas Tencer¹, Stan Li² and Vibeke Strand³, ¹33 Technology Drive, Celgene Corporation, Warren, NJ, ²Celgene Corporation, Warren, NJ, ³Biopharmaceutical Consultant, Portola Valley, CA
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the aberrant immune response that causes the joint symptoms, systemic inflammation, and skin…
Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Saedis Saevarsdottir¹, Michele Santacatterina², Carl Turesson³, Helena Forsblad⁴, Lennart Jacobsson⁴ and Staffan Lindblad⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
Abstract Number: 1595 • 2014 ACR/ARHP Annual Meeting
Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States
Thomas Tencer¹, Zoe Clancy¹, Helene Cawston², Sandrine Cure³ and Frank Zhang¹, ¹33 Technology Drive, Celgene Corporation, Warren, NJ, ²OptumInsight, Nanterre, France, ³OptumInsight, Uxbridge, United Kingdom
Background/Purpose: In the treatment of psoriatic arthritis (PsA), switching between alternative biologic treatments is common. A cost-effectiveness model was developed to assess the impact of…
Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting
Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis
Doquyen H. Huynh¹, Carol J. Etzel^2,3, Vanessa Cox⁴, Philip J. Mease⁵ and Arthur Kavanaugh⁶, ¹Rheumatology, UC San Diego School of Medicine, San Diego, CA, ²PO Box 786, Corrona, LLC., Southborough, MA, ³Department of Epidemiology, UT MD Anderson, Houston, TX, ⁴CORRONA, Inc, Southborough, MA, ⁵CORRONA, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…
Abstract Number: 1593 • 2014 ACR/ARHP Annual Meeting
Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis
Vinod Chandran¹, Arane Thavaneswaran² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. There are few biomarkers for disease activity in PsA. Traditional acute phase reactants are…
Abstract Number: 1592 • 2014 ACR/ARHP Annual Meeting
Ability of Clinical Variables to Predict Radiographic Damage in Psoriatic Arthritis
Vinod Chandran¹, Arane Thavaneswaran², Richard J. Cook³ and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis associated with psoriasis that leads to progressive joint damage. Biomarkers in addition to clinical features may help…
Abstract Number: 1591 • 2014 ACR/ARHP Annual Meeting
Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis
M. Elaine Husni¹, Danielle Brennan², WH Wilson Tang³ and Stanley Hazen³, ¹Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiology, CCF, Cleveland, OH
Background/Purpose Psoriatic diseases are systemic inflammatory joint and skin disorders associated with increased cardiovascular (CV) morbidity. Paraoxonase (PON) and Arylesterase (ARYL) are antioxidant enzymatic proteins…
Abstract Number: 1590 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephan Hall⁵, Eric Lespessailles⁶, Philip J. Mease⁷, Georg A. Schett⁸, ChiaChi Hu⁹, Randall M. Stevens⁹ and Jürgen Wollenhaupt¹⁰, ¹University of California San Diego, La Jolla, CA, ²University of Sheffield, Sheffield, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁵Cabrini Health and Monash University, Melbourne, Australia, ⁶University of Orléans, Orléans, France, ⁷Swedish Medical Center and University of Washington, Seattle, WA, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor that may modify the immune response, has been shown effective in psoriatic arthritis (PsA). PALACE 1 compared…
Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…
Abstract Number: 1588 • 2014 ACR/ARHP Annual Meeting
Resistance Training in Patients with Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life
Diego Roger Silva¹, Fabio Jennings¹, Emilia Moreira¹ and Jamil Natour², ¹Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Internal Medicine, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose Psoriatic arthritis (PSA) is a chronic inflammatory arthritis, defined as the association of inflammatory arthropathy and skin psoriasis. The literature is still very scarce…
Abstract Number: 1587 • 2014 ACR/ARHP Annual Meeting
The Economic Impact of Psoriatic Arthritis in Toronto, Ontario
Dafna D. Gladman^1,2, Melissa Yu¹, Michal Bohdanowicz¹, Arane Thavaneswaran³ and Vinod Chandran^1,4, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: This study aimed to quantify the direct and indirect costs of psoriatic arthritis (PsA) at a single center in Toronto, Ontario and to assess…
Abstract Number: 1586 • 2014 ACR/ARHP Annual Meeting
Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers
Daniela Cretu¹, Kun Liang², Dafna D. Gladman³, Eleftherios Diamandis⁴ and Vinod Chandran³, ¹Laboratory Medicine and Pathobiology, Unviersity of Toronto, Mount Sinai Hospital, Ontario, Canada, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Background/Purpose Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in…
Abstract Number: 1585 • 2014 ACR/ARHP Annual Meeting
Presence of Swollen and Tender Joints in Patients Fulfilling Minimal Disease Activity Criteria
Josefina Marin¹, Maria L. Acosta Felquer², Leandro Ferreyra-Garrot¹, Santiago Ruta³, Javier Rosa¹ and Enrique R. Soriano⁴, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Internal Medicine, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose Minimal disease activity (MDA) is a composite measure created for patients with psoriatic arthritis (PsA) that encompasses many clinically important aspects of PsA: arthritis,…
Abstract Number: 1584 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis
Pinar Cetin¹, Dilek Solmaz², Murat Keser³, Ismail Sari¹, Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, ³Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being, which was used in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].